Zongertinib Gets Accelerated FDA Nod for HER2 NSCLC

Publisher: The Insight Partners

New York | August 13, 2025- A major shift has occurred in the treatment of a rare, aggressive form of non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib (Hernexeos), the first oral targeted therapy for adults with unresectable or metastatic non-squamous NSCLC driven by HER2 (ERBB2) tyrosine kinase domain (TKD) mutations. This treatment is intended for patients who have already received other systemic therapies.

This approval marks a major milestone for patients with limited treatment options. It also highlights the growing role of comprehensive biomarker testing, such as next-generation sequencing (NGS), in personalizing care. These tools can detect HER2 mutations in approximately 2–4% of NSCLC cases. To support the rollout, the FDA also approved the Oncomine Dx Target Test as a companion diagnostic.

Clinical data from the Phase Ib Beamion LUNG-1 trial shows zongertinib's strong efficacy. Among patients who had received platinum-based chemotherapy but were new to HER2-targeted drugs, the overall response rate (ORR) reached 75%. Over half of these patients (58%) maintained their response for six months or longer.

In a separate group with prior HER2-directed treatment and chemotherapy, zongertinib still achieved a 44% ORR. Around 27% of these patients saw responses lasting six months or more. The median progression-free survival (PFS) stood at 12.4 months, and the median duration of response (DOR) reached 14.1 months, reflecting a sustained therapeutic benefit.

Zongertinib’s once-daily, oral dosing adds further convenience. The dose depends on body weight: 120 mg for patients under 90 kg and 180 mg for those 90 kg or more. It can be taken with or without food and continued until disease progression or unacceptable side effects arise.

While the drug’s continued availability depends on results from the ongoing Phase III Beamion LUNG-2 trial, which compares it to standard care, this approval already offers new hope. For patients with HER2-mutant NSCLC, zongertinib represents a much-needed breakthrough.